Concepts and targets in triple-negative breast cancer: recent results and clinical implications

Concepts and targets in triple-negative breast cancer: recent results and clinical implications

Triple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) receptor. No targeted therapies are available for the treatment of...

Full description

Bibliographic Details
Main Authors: Poornima Saha, Rita Nanda
Format: Article
Language:English
Published: SAGE Publishing 2016-09-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758834016657071
id doaj-c38c1acdbc4f4c8a8a18a60ed40d8efc
record_format Article
spelling doaj-c38c1acdbc4f4c8a8a18a60ed40d8efc2020-11-25T02:53:44ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83401758-83592016-09-01810.1177/1758834016657071Concepts and targets in triple-negative breast cancer: recent results and clinical implicationsPoornima SahaRita NandaTriple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) receptor. No targeted therapies are available for the treatment of TNBC, and chemotherapy remains the standard of care. Gene expression profiling has identified six distinct molecular subtypes of TNBC. The identification of novel targets, coupled with the development of therapies for different subsets of TNBC, holds great promise for the future treatment of this aggressive form of breast cancer. This review focuses on novel therapies in development for the treatment of TNBC.https://doi.org/10.1177/1758834016657071
collection DOAJ
language English
format Article
sources DOAJ
author Poornima Saha
Rita Nanda
spellingShingle Poornima Saha
Rita Nanda
Concepts and targets in triple-negative breast cancer: recent results and clinical implications
Therapeutic Advances in Medical Oncology
author_facet Poornima Saha
Rita Nanda
author_sort Poornima Saha
title Concepts and targets in triple-negative breast cancer: recent results and clinical implications
title_short Concepts and targets in triple-negative breast cancer: recent results and clinical implications
title_full Concepts and targets in triple-negative breast cancer: recent results and clinical implications
title_fullStr Concepts and targets in triple-negative breast cancer: recent results and clinical implications
title_full_unstemmed Concepts and targets in triple-negative breast cancer: recent results and clinical implications
title_sort concepts and targets in triple-negative breast cancer: recent results and clinical implications
publisher SAGE Publishing
series Therapeutic Advances in Medical Oncology
issn 1758-8340
1758-8359
publishDate 2016-09-01
description Triple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) receptor. No targeted therapies are available for the treatment of TNBC, and chemotherapy remains the standard of care. Gene expression profiling has identified six distinct molecular subtypes of TNBC. The identification of novel targets, coupled with the development of therapies for different subsets of TNBC, holds great promise for the future treatment of this aggressive form of breast cancer. This review focuses on novel therapies in development for the treatment of TNBC.
url https://doi.org/10.1177/1758834016657071
work_keys_str_mv AT poornimasaha conceptsandtargetsintriplenegativebreastcancerrecentresultsandclinicalimplications
AT ritananda conceptsandtargetsintriplenegativebreastcancerrecentresultsandclinicalimplications
_version_ 1724724771235561472

Similar Items